Viking Therapeutics (VKTX)
NASDAQ:VKTX
Want to see VKTX full AI Analyst Report?
Top Page
Viking Therapeutics
(NASDAQ:VKTX)
Select Model
Select Model
Rating:53Neutral
Price Target:
$32.00
▼(-9.09% Downside)
Action:ReiteratedDate:04/30/26
The score is held back primarily by weak financial performance (pre-revenue with rapidly increasing losses and cash burn), while the earnings call provides meaningful support due to strong clinical efficacy and a clear, catalyst-heavy 2026 development roadmap. Technicals remain bearish, and valuation is constrained by ongoing losses and no dividend.
Positive Factors
Clinical Efficacy
Robust Phase II efficacy for oral VK2735 (notable mean weight loss and high ≥10% responder rates) materially strengthens the drug’s clinical differentiation. Durable efficacy increases the likelihood of successful Phase III outcomes, regulatory confidence, and stronger payer/commercial positioning over the next 2–6 months.
Negative Factors
High Cash Burn
Very large and accelerating operating and free cash outflows create structural refinancing and dilution risk. Even with stated runway, sustained $60M–$90M quarterly burn means capital markets or partners will likely be required to complete late‑stage programs, constraining long‑term financial flexibility.
Read all positive and negative factors
Positive Factors
Negative Factors
Clinical Efficacy
Robust Phase II efficacy for oral VK2735 (notable mean weight loss and high ≥10% responder rates) materially strengthens the drug’s clinical differentiation. Durable efficacy increases the likelihood of successful Phase III outcomes, regulatory confidence, and stronger payer/commercial positioning over the next 2–6 months.
Read all positive factors
Viking Therapeutics (VKTX) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$3.64B
Dividend YieldN/A
Average Volume (3M)2.26M
Price to Earnings (P/E)―
Beta (1Y)1.17
Revenue GrowthN/A
EPS Growth-259.98%
CountryUS
Employees45
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-4.14
Shares Outstanding116,105,644
10 Day Avg. Volume1,926,578
30 Day Avg. Volume2,255,432
Financial Highlights & Ratios
PEG Ratio-0.05
Price to Book (P/B)6.20
Price to Sales (P/S)0.00
P/FCF Ratio-14.22
Enterprise Value/Market Cap0.97
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-37.44K
Enterprise Value/Ebitda-7.01
Forecast
1Y Price Target
$89.72Price Target Upside154.88% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering13
EPS Forecast (FY)-4.01
Revenue Forecast (FY)N/A
Viking Therapeutics Business Overview & Revenue Model
Company Description
Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtyp...
How the Company Makes Money
As a clinical-stage biopharmaceutical company, Viking Therapeutics generally does not generate recurring revenue from selling approved drugs (if product-sales revenue is not publicly available for the period in question, it is null). Instead, its ...
Viking Therapeutics Earnings Call Summary
Earnings Call Date:Feb 11, 2026
(Q4-2025)
| % Change Since: |
Next Earnings Date:Jul 29, 2026
Earnings Call Sentiment Positive
The call emphasized substantial clinical and operational progress: compelling Phase II efficacy for both subcutaneous (up to 14.7%) and oral (up to 12.2%, with 80% ≥10% responders), initiation and fast enrollment of Phase III programs, completion of auto-injector bioequivalence enabling device rollout, a completed maintenance study enrollment with results expected Q3 2026, a manufacturing agreement to support commercialization, and expansion of the pipeline with an amylin agonist. Offsetting these positives are sharply higher R&D expenses and widening net losses (large YoY increases), a ~22% decline in cash year-over-year, and a projected quarterly burn of $60M–$90M, alongside marketplace and reimbursement uncertainties. On balance, the operational and clinical milestones materially outweigh the financial and market risks presented on the call.Positive Updates
Robust Phase II Efficacy — Subcutaneous VK2735
Phase II VENTURE subcutaneous results showed statistically significant weight loss up to 14.7% after 13 weekly doses; Phase I subcutaneous cohorts showed up to ~8% weight loss after 4 weekly doses. Safety/tolerability described as encouraging with most adverse events mild or moderate.
Negative Updates
Sharp Increase in R&D Spend
R&D expenses rose materially as trials progressed: Q4 R&D of $153.5M vs $31.0M in Q4 2024 (≈+395%); full-year R&D $345.0M vs $101.6M in 2024 (≈+240%). Increases driven by Phase III activity, manufacturing, stock comp and personnel.
Read all updates
Q4-2025 Updates
Positive
Negative
Robust Phase II Efficacy — Subcutaneous VK2735
Phase II VENTURE subcutaneous results showed statistically significant weight loss up to 14.7% after 13 weekly doses; Phase I subcutaneous cohorts showed up to ~8% weight loss after 4 weekly doses. Safety/tolerability described as encouraging with most adverse events mild or moderate.
Read all positive updates
Company Guidance
Viking guided to a busy 2026 cadence: they expect to initiate the oral VK2735 Phase III program in Q3 2026, report maintenance study results in Q3 2026 (the maintenance study completed enrollment and runs weekly dosing through week 19 with a study end at week 31 and includes monthly, every‑other‑week and weekly subcu arms plus weekly/daily oral arms), complete VANQUISH‑2 enrollment and roll out an auto‑injector in Q1 2026 (VANQUISH‑1 exceeded its ~4,500‑patient target and VANQUISH‑2 is targeting ~1,100 patients), and file an IND for their lead amylin agonist later this quarter with first dosing likely in Q2 2026; the Phase III VANQUISH studies are 78‑week trials with 7.5, 12.5 and 17.5 mg weekly dose arms, and Viking said its $706 million cash, cash equivalents and short‑term investments (down from $903M a year earlier) should fund through these catalysts and top‑line oral Phase III readouts, with expected quarterly R&D cash use of roughly $60–$90 million; prior clinical benchmarks cited included subcu VENTURE weight loss up to 14.7% at 13 weeks and oral VENTURE up to 12.2% at 13 weeks (up to 80% of oral recipients achieved ≥10% vs 5% placebo).Viking Therapeutics Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
68
Positive
Cash Flow
22
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -94.00K | -431.00K | 0.00 | -292.00K | 0.00 | 0.00 |
| EBITDA | -501.77M | -393.34M | -150.57M | -100.53M | -70.06M | -55.39M |
| Net Income | -472.33M | -359.64M | -109.96M | -85.89M | -68.87M | -54.99M |
Balance Sheet | ||||||
| Total Assets | 608.24M | 715.73M | 908.32M | 368.49M | 168.53M | 210.66M |
| Cash, Cash Equivalents and Short-Term Investments | 602.96M | 705.74M | 902.61M | 362.08M | 155.49M | 202.10M |
| Total Debt | 0.00 | 137.00K | 1.12M | 1.26M | 1.56M | 29.00K |
| Total Liabilities | 106.33M | 76.67M | 28.04M | 20.07M | 23.21M | 8.78M |
| Stockholders Equity | 501.92M | 639.06M | 880.28M | 348.42M | 145.32M | 201.88M |
Cash Flow | ||||||
| Free Cash Flow | -340.33M | -278.69M | -87.79M | -73.38M | -48.40M | -47.59M |
| Operating Cash Flow | -340.33M | -278.69M | -87.79M | -73.38M | -48.40M | -47.59M |
| Investing Cash Flow | 332.33M | 341.39M | -553.37M | -179.09M | 54.75M | 37.96M |
| Financing Cash Flow | 88.17M | 76.44M | 612.46M | 271.38M | 4.16M | 6.88M |
Viking Therapeutics Technical Analysis
Positive
35.20
Price Trends
32.84
Positive
33.50
Positive
32.63
Positive
Market Momentum
0.62
Negative
55.96
Neutral
67.84
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For VKTX, the sentiment is Positive. The current price of 35.2 is above the 20-day moving average (MA) of 33.72, above the 50-day MA of 32.84, and above the 200-day MA of 32.63, indicating a bullish trend. The MACD of 0.62 indicates Negative momentum. The RSI at 55.96 is Neutral, neither overbought nor oversold. The STOCH value of 67.84 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for VKTX.
Viking Therapeutics Risk Analysis
Viking Therapeutics disclosed 76 risk factors in its most recent earnings report. Viking Therapeutics reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Viking Therapeutics Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
62 Neutral | $5.39B | -12.41 | -48.47% | ― | -100.00% | -46.29% | |
62 Neutral | $5.89B | -10.43 | -65.80% | ― | ― | -2.53% | |
56 Neutral | $5.80B | -14.83 | -145.91% | ― | ― | -35.59% | |
56 Neutral | $4.53B | -20.01 | -23.02% | ― | -52.13% | 3.91% | |
54 Neutral | $2.57B | -2.85 | 1566.94% | ― | 13.33% | -3.82% | |
53 Neutral | $3.64B | -5.94 | -71.31% | ― | ― | -259.98% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
VKTX
Viking Therapeutics
31.33
3.78
13.72%
RARE
Ultragenyx Pharmaceutical
26.12
-8.99
-25.61%
XENE
Xenon
56.44
21.42
61.17%
SRRK
Scholar Rock Holding
48.39
17.72
57.78%
IMVT
Immunovant
28.94
14.92
106.42%
NAMS
NewAmsterdam Pharma Company
38.73
20.36
110.83%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.